|
Researchers Find New Treatment for Hepatitis C
May 15, 2008Oklahoma City, OK -- Researchers at the OU Health Sciences Center have found a new use for an old drug. Their findings appear online Friday in the American Journal of Gastroenterology.
The drug, Fluvastatin, has been approved since 1993 by the U.S. Food and Drug Administration for the treatment of elevated cholesterol in adults. Millions of patients have taken Fluvastatin for cholesterol without difficulty.
In a study of 31 veterans at the Veteran's Administration Medical Center in Oklahoma City, researchers found that Fluvastatin significantly lowered the viral load, or levels of hepatitis C virus, for up to six weeks when used alone. Hepatitis C is the disease that claimed the life of Oklahoman Mickey Mantle.
"This research is the first to demonstrate the antiviral activity of Fluvastatin in human beings infected with hepatitis C, most of whom were non-responders to the standard of care treatment," said Ted Bader, M.D., the principle investigator on the project and the director of liver diseases at the OU Health Sciences Center.
Since Fluvastatin will not completely clear the hepatitis C virus by itself, researchers have started a phase II randomized, controlled trial that combines Fluvastatin with the standard treatment of peg-interferon and ribavirin. They hope to use the combination of medicines to significantly improve the cure rate for hepatitis C. After further required testing and approval, the drug could be available as a new treatment for hepatitis C far sooner than any other anti-hepatitis C drug currently under research and development.
"We need additional drugs to add to this regimen to improve the cure rate," Bader said. "When patients are cured, they feel dramatically better, their health care costs plummet, their risk of liver cancer drops dramatically, and if they do not have cirrhosis, they will not need a liver transplant. Moreover, they are no longer infectious."
In the initial investigative study funded by the VA Research Foundation of Oklahoma City and Dr. Michael Bronze at the OU College of Medicine, veterans with chronic HCV were given oral doses of Fluvastatin daily for two to 12 weeks. Within a month, half of the patients showed a reduction of the virus. One patient's viral load was about 50 times lower than before taking Fluvastatin.
Hepatitis C is a significant problem for Oklahoma. More than 80,000 Oklahomans have chronic hepatitis C (HCV), but less than 5 percent have been treated. HCV is the leading cause of liver-related deaths in our state and also is the cause for the majority of the 70 liver transplants performed in Oklahoma each year.
Nationwide, 2 percent of Americans (about 4 million) are infected with chronic hepatitis C, which is four times the number of patients infected with HIV. Chronic hepatitis C is often asymptomatic and can lead to progressive liver disease.
Most people with hepatitis C contracted the disease through blood transfusions before 1992 when a test was implemented to screen for the disease. You also can get the virus by injecting drugs with contaminated needles and, less commonly, from contaminated needles used in tattooing and body piercing.
University of Oklahoma
"This research is the first to demonstrate the antiviral activity of Fluvastatin in human beings infected with hepatitis C, most of whom were non-responders to the standard of care treatment," said Ted Bader, M.D., the principle investigator on the project and the director of liver diseases at the OU Health Sciences Center.
Since Fluvastatin will not completely clear the hepatitis C virus by itself, researchers have started a phase II randomized, controlled trial that combines Fluvastatin with the standard treatment of peg-interferon and ribavirin. They hope to use the combination of medicines to significantly improve the cure rate for hepatitis C. After further required testing and approval, the drug could be available as a new treatment for hepatitis C far sooner than any other anti-hepatitis C drug currently under research and development.
"We need additional drugs to add to this regimen to improve the cure rate," Bader said. "When patients are cured, they feel dramatically better, their health care costs plummet, their risk of liver cancer drops dramatically, and if they do not have cirrhosis, they will not need a liver transplant. Moreover, they are no longer infectious."
In the initial investigative study funded by the VA Research Foundation of Oklahoma City and Dr. Michael Bronze at the OU College of Medicine, veterans with chronic HCV were given oral doses of Fluvastatin daily for two to 12 weeks. Within a month, half of the patients showed a reduction of the virus. One patient's viral load was about 50 times lower than before taking Fluvastatin.
Hepatitis C is a significant problem for Oklahoma. More than 80,000 Oklahomans have chronic hepatitis C (HCV), but less than 5 percent have been treated. HCV is the leading cause of liver-related deaths in our state and also is the cause for the majority of the 70 liver transplants performed in Oklahoma each year.
Nationwide, 2 percent of Americans (about 4 million) are infected with chronic hepatitis C, which is four times the number of patients infected with HIV. Chronic hepatitis C is often asymptomatic and can lead to progressive liver disease.
Most people with hepatitis C contracted the disease through blood transfusions before 1992 when a test was implemented to screen for the disease. You also can get the virus by injecting drugs with contaminated needles and, less commonly, from contaminated needles used in tattooing and body piercing.
University of Oklahoma
Hepatitis News and Current Hepatitis Events RSSNew Guidelines for Treating Rheumatoid Arthritis
Proven combinations of medicines and the introduction of new anti-arthritis drugs have significantly improved the treatment of rheumatoid arthritis (RA), according to guidelines issued by the American College of Rheumatology and co-authored by physicians at the University of Alabama at Birmingham (UAB).
Older liver donors not associated with negative outcomes in transplant recipients with hepatitis C
Receiving a liver from a donor older than age 60 does not appear to be associated with transplant failure, death or recurrent disease in the next five years among transplant patients with the hepatitis C virus.
Hepatitis C virus may need enzyme's help to cause liver disease
A key enzyme may explain how hepatitis C infection causes fatty liver - a buildup of excess fat in the liver, which can lead to life-threatening diseases such as cirrhosis and liver cancer, report University of Pittsburgh Graduate School of Public Health and School of Medicine researchers.
Fungi the cause of many outbreaks of disease but mostly ignored
Fungi can cause a number of life-threatening diseases but they also are becoming increasingly useful to science and manufacturing every year.
State policies influence drug treatment programs
State policies have a significant impact on the services performed by substance abuse treatment programs, and could play a key role in efforts to expand the use of research-based "comprehensive" treatment approaches, reports a study in the June issue of the Journal of Substance Abuse Treatment (JSAT).
Radical reform is needed to stop the 'inhumane' practice of transplant tourism
The UK government must bring in presumed consent to organ donation or allow a controlled donor compensation programme for unrelated live donors, in order to bring the "inhumane" practice of transplant tourism from the UK to an end, claims a doctor in this week's BMJ.
An unexpected link between coronavirus replication and protein secretion in infected cells
Coronavirus replication is critically linked to two factors within the early secretory pathway, according to new findings by a team of Dutch researchers that are published June 13th in the open-access journal PLoS Pathogens.
Fatty liver linked to increased risk of diabetic kidney disease
For patients with type 2 diabetes, a condition called non-alcoholic fatty liver disease (NAFLD) may be an important risk factor for diabetes-related chronic kidney disease (CKD), according to a study in the August Journal of the American Society of Nephrology (JASN).
Researchers from 5 countries to test hygiene hypothesis with EU funding
High living standards and the life style connected to them seem to promote the development of autoimmune diseases and allergic symptoms. This has lead to the assumption that the immune system begins to overreact to the organism's own structures or to exogenous non-infectious proteins, i.e. allergens, when it does not have to work hard enough to protect the individual from infections.
Tool creates personalized catch-up immunization schedules for missed childhood vaccinations
A new downloadable software tool will help pediatricians, parents and other health care professionals determine how to adjust complex childhood immunization schedules when one or more vaccine doses aren't received at the proper time.
More Hepatitis News Articles
 | Dr. Melissa Palmer's Guide To Hepatitis and Liver Disease by Melissa Palmer |
 | The Hepatitis C Help Book, Revised Edition: A Groundbreaking Treatment Program Combining Western and Eastern Medicine for Maximum Wellness and Healing by Misha Ruth Cohen, Robert Gish, Kalia Doner |
 | Hepatitis C Cookbook: Easy and Delicious Recipes by Heather Jeanne |
 | Herbs for Hepatitis C and the Liver (A Storey Medicinal Herb Guide) by Stephen Harrod Buhner |
 | Living With Hepatitis C For Dummies by Nina L. Paul |
 | Hepatitis C Free: Alternative Medicine VS, The Drug Industry, The People Speak by Lloyd Wright |
 | Living with Hepatitis C: A Survivor's Guide, Fourth Edition (Living with) by Gregory T. Everson, Hedy Weinberg |
 | Living Healthy with Hepatitis C: Natural and Conventional Approaches to Recover Your Quality of Life by Harriet A. Washington |
 | Basic Infection Control for Healthcare Providers by Michael Kennamer |
 | Triumph Over Hepatitis C by Lloyd Wright |
| © 2008 BrightSurf.com |